GlassScriptPhysician profile
Matthew C Upshaw
NPI 1407842487
$5,725.31
in general payments reported to CMS, 2019-2025
38 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $373 · 2021: $925 · 2022: $874 · 2023: $1,403 · 2024: $801 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.54 |
| Education | $390.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $966.27 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $805.12 | 2019-2025 | |
| Amgen INC. | $376.22 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $356.69 | 2019-2024 | Spravato |
| Hologic Sales and Service, LLC | $352.70 | 2019-2023 | Thinprep 2000 Processor, Aptima |
| Abbvie INC. | $302.76 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $300.91 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $247.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $228.31 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $177.10 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $158.43 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.02 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $153.21 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $104.40 | 2019-2025 | Ozempic, Wegovy |
| Gen-Probe Sales & Service, INC. | $99.72 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.17 | 2024-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $90.28 | 2023 | Quviviq |
| Boston Scientific Corporation | $77.89 | 2020-2021 | |
| Sanofi Pasteur INC. | $75.39 | 2022-2025 | |
| Astellas Pharma US INC | $73.82 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $65.00 | 2023 | |
| Esperion Therapeutics, INC. | $63.05 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $58.75 | 2019-2025 | Austedo Xr |
| Exact Sciences Corporation | $43.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.53 | 2021-2022 | |
| Edwards Lifesciences Corporation | $36.16 | 2023-2024 | Sapien 3 Ultra Resilia |
| Organon LLC | $30.23 | 2023 | Nexplanon |
| Abbott Laboratories | $24.20 | 2025 | Proclaim |
| Daiichi Sankyo INC. | $22.91 | 2021 | |
| Dexcom, INC. | $19.20 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $19.19 | 2024 | Qutenza |
| Si-Bone, INC. | $18.75 | 2021 | |
| Amarin Pharma, INC. | $14.69 | 2020 | |
| Sumitomo Pharma America, INC. | $14.65 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $14.62 | 2024 | Amvuttra |
| Lundbeck LLC | $13.63 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $13.46 | 2021 | |
| Coala Life INC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Upshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.